Bostwick Labs to Market MDxHealth's Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – MDxHealth and Bostwick Laboratories today announced a marketing agreement covering MDxHealth's ConfirmMDx prostate cancer test.

The deal, they said, provides MDxHealth with access to one of the largest urology networks in the US. Bostwick specializes in anatomic and clinical pathology.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.